Tumor antigen-specific CD4-positive T cell

Tumor antigen-specific CD4-positive T cells are a subset of helper T lymphocytes that recognize and respond to specific antigens presented by tumors via MHC class II molecules. Contrary to earlier views that focused on their "helper" role for CD8 T cells, these cells exhibit direct cytotoxicity (if the tumor expresses MHC II), activate macrophages leading to tumor destruction, induce growth arrest and senescence in tumor cells, and facilitate the recruitment and function of other immune effector cells. Adoptive transfer of these cells, or pharmacologic expansion and activation, forms the basis for emerging cancer immunotherapies, both alone and in combination with checkpoint inhibitors. Their therapeutic relevance has been confirmed in several preclinical and early clinical studies, though safety and efficacy depend on antigen specificity, functional phenotype, and resistance to functional exhaustion.

Other names

Tumor antigen-specific helper T cellTumor antigen-specific CD4+ T cellTumor-reactive CD4 T cellTumor-specific CD4-positive T cell

Recognition of tumor antigen–MHC II complex by CD4 TCR. Direct MHC II-restricted cytolytic activity via perforin/granzyme. Cytokine secretion (IFN-γ, TNF-α) inducing senescence, apoptosis, or anti-angiogenesis. Activation of macrophages leading to NO-mediated tumor cell killing. Enhancement of CD8 T cell and antibody-mediated (B cell) responses.